Immuno-Oncology

Protagen develops precision diagnostics tools that allow for the prediction of response to therapy and irAE onset, giving pharmaceutical and biotech companies the power to develop safer drugs, and enabling clinicians to select the right therapy for the right patient.

The field of immuno-oncology is rapidly evolving, and the quest to successfully treat and potentially cure cancer is the opportunity of a lifetime. However, although the field has had some significant breakthroughs in the past decade, there are still a number of issues that stand to hold back the progress of this promising area.

Many cancer patients fail to respond to therapy or even develop harmful immune-related Adverse Events (irAEs). This has led not only to the FDA halting clinical trials in some cases, but also to clinicians running the risk of triggering these effects in patients undergoing immunotherapy.

Protagen is dedicated to the development of precision medicine tools that allow for the prediction of response to therapy and irAE onset, giving pharmaceutical and biotech companies the power to develop safer drugs, and enabling clinicians to select the right therapy for the right patient.

From just a simple drop of blood, analyzing a patient’s autoantibody signature can enable us to:

  • Detect and predict the onset of sometimes-fatal irAEs in patients undergoing immunotherapy.
  • Predict therapeutic response for those undergoing immunotherapy, which will enable clinicians to better understand the therapy and improve treatment decisions.
  • Monitor treatment response and irAEs incidence as some patients adapt to immunotherapy, and/or become resistant to its effects.

Download the eBook to find out more about the power of autoantibodies to improve the success of cancer immunotherapy.

Immuno-Oncology Applications

Protagen is able to detect autoantibodies for the prediction and monitoring of immune-related adverse events (irAEs), as well as therapeutic response for patients undergoing cancer immunotherapy.

 

NavigAID for Immuno-Oncology

Protagen is expanding its NavigAID offering to support the development of immunotherapeutic anticancer drugs, owing to the role played by autoantibodies in cancer as well as autoimmune disease.

 

SeroTag® Platform

SeroTag® is Protagen’s proprietary biomarker discovery engine, which is used to discover and validate novel biomarkers that can help stratify different cancer indications and autoimmune diseases.

 

Get in touch

Improving the treatment of cancer and autoimmune disease is our passion, and we always welcome the chance to discuss these topics with current and prospective customers, patients and clinicians alike.

We sometimes like to share the latest industry insights and company news, would you like to be added to our database?

13 + 11 =

Copyright © 1997-2018
Protagen AGDortmund, Germany